Literature DB >> 10733939

CD39 modulates IL-1 release from activated endothelial cells.

M Imai1, C Goepfert, E Kaczmarek, S C Robson.   

Abstract

The activation of endothelial cells (EC) and monocyte-macrophages (Mφ) by lipopolysaccharide (LPS) is considered an important element of the vascular injury observed in endotoxemia. Interleukin-1 (IL-1) beta release from Mφ in response to LPS, appears to be mediated by the autocrine/paracrine release of ATP via P2X7 receptor activation. In EC, similar nucleotide-mediated signaling pathways may be influenced by high levels of expression of CD39, the vascular nucleoside triphosphate diphosphohydrolase (NTPDase; ENTPD I). To determine whether CD39 modulates ATP-mediated release of IL-1 from EC, we stimulated human EC with LPS and measured levels of ATP secretion and IL-1 release. LPS triggered ATP secretion from EC that was soon followed by IL-1alpha release. Overexpression of CD39 following infection with recombinant CD39 adenoviral vectors (AdCD39) abrogated the initial phase of ATP secretion and inhibited IL-1alpha release; comparable results were obtained with soluble NTPDase. These data demonstrate that CD39/NTPDase modulates IL-1alpha release from LPS stimulated human EC. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733939     DOI: 10.1006/bbrc.2000.2410

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo.

Authors:  Filip Kukulski; Fethia Ben Yebdri; Julie Lefebvre; Michel Warny; Philippe A Tessier; Jean Sévigny
Journal:  J Leukoc Biol       Date:  2007-02-22       Impact factor: 4.962

2.  NTPDase1 governs P2X7-dependent functions in murine macrophages.

Authors:  Sébastien A Lévesque; Filip Kukulski; Keiichi Enjyoji; Simon C Robson; Jean Sévigny
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

3.  Regulation of ecto-5'-nucleotidase by TNF-alpha in human endothelial cells.

Authors:  Kameljit Kalsi; Charlotte Lawson; Martin Dominguez; Patricia Taylor; Magdi H Yacoub; Ryszard T Smolenski
Journal:  Mol Cell Biochem       Date:  2002-03       Impact factor: 3.396

Review 4.  P2 receptors: new potential players in atherosclerosis.

Authors:  Francesco Di Virgilio; Anna Solini
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 5.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

6.  P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells.

Authors:  H L Wilson; R W Varcoe; L Stokes; K L Holland; S E Francis; S K Dower; A Surprenant; D C Crossman
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

7.  High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population.

Authors:  Halima Moncrieffe; Kiran Nistala; Yasmine Kamhieh; Jamie Evans; Ayad Eddaoudi; Simon Eaton; Lucy R Wedderburn
Journal:  J Immunol       Date:  2010-05-24       Impact factor: 5.422

8.  Transient changes in the localization and activity of ecto-nucleotidases in rat hippocampus following lipopolysaccharide treatment.

Authors:  Agnes Kittel; Beata Sperlágh; Julie Pelletier; Jean Sévigny; Terence L Kirley
Journal:  Int J Dev Neurosci       Date:  2007-05-17       Impact factor: 2.457

Review 9.  Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on host-pathogen interactions.

Authors:  Fiona M Sansom; Simon C Robson; Elizabeth L Hartland
Journal:  Microbiol Mol Biol Rev       Date:  2008-12       Impact factor: 11.056

Review 10.  Basal release of ATP: an autocrine-paracrine mechanism for cell regulation.

Authors:  Ross Corriden; Paul A Insel
Journal:  Sci Signal       Date:  2010-01-12       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.